_id
690db60dccc777a4e85d0e00
Ticker
BCTXW
Name
BriaCell Therapeutics Corp
Exchange
NASDAQ
Address
Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
Country
USA
Sector
Industry
Currency
USD
Website
https://briacell.com
Description
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Last Close
0.0645
Volume
2041
Current Price
0.021
Change
-0.0059
Last Updated
2026-01-20T16:21:16.296Z
Image
data:image/webp;base64,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
Ipo Date
2021-02-24T00:00:00.000Z
Market Cap
48083940
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
-
Target Price
-
Strong Buy
-
Buy
-
Hold
-
Sell
-
Strong Sell
-
Current Quarter
2025-10-31
Revenue
0
Cost Of Revenue
26390
Gross Profit
-26390
Operating Expenses
8322943
Operating Income
-8239797
Interest Expense
-
Pretax Income
-8197565
Net Income
-8115671
Eps
-4.3078959353598325
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
-8169238
Operating Margin
-
Total Other Income Expense Net
44169
Cash
2714012
Short Term Investments
7461960
Receivables
1172435
Inventories
-
Total Current Assets
11348407
Property Plant Equipment
273980
Total Assets
13075050
Payables
2128915
Short Term Debt
-
Long Term Debt
-
Total Liabilities
3724646
Equity
9350404
Bs_currency_symbol
USD
Depreciation
26657
Change In Working Capital
225370
Cash From Operations
-7627825
Capital Expenditures
0
Cash From Investing
-74250
Cash From Financing
0
Net Change In Cash
-7779796
Cf_currency_symbol
USD
PE
-
PB
0.004231049909715131
ROE
-86.79487003983999
ROA
-62.06990413038574
FCF
-7627825
Fcf Percent
-
Piotroski FScore
1
Health Score
42
Deep Value Investing Score
5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-10-31
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
26390
Quarters > 0 > income Statement > gross Profit
-26390
Quarters > 0 > income Statement > operating Expenses
8322943
Quarters > 0 > income Statement > operating Income
-8239797
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-8197565
Quarters > 0 > income Statement > net Income
-8115671
Quarters > 0 > income Statement > eps
-4.3078959353598325
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1883906
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-8169238
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
44169
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
2714012
Quarters > 0 > balance Sheet > short Term Investments
7461960
Quarters > 0 > balance Sheet > receivables
1172435
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
11348407
Quarters > 0 > balance Sheet > property Plant Equipment
273980
Quarters > 0 > balance Sheet > total Assets
13075050
Quarters > 0 > balance Sheet > payables
2128915
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
3724646
Quarters > 0 > balance Sheet > equity
9350404
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-8278328
Quarters > 0 > cash Flow > depreciation
26657
Quarters > 0 > cash Flow > change In Working Capital
225370
Quarters > 0 > cash Flow > cash From Operations
-7627825
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-74250
Quarters > 0 > cash Flow > cash From Financing
0
Quarters > 0 > cash Flow > net Change In Cash
-7779796
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-4.3078959353598325
Quarters > 0 > ratios > PB
0.004231049909715131
Quarters > 0 > ratios > ROE
-86.79487003983999
Quarters > 0 > ratios > ROA
-62.06990413038574
Quarters > 0 > ratios > FCF
-7627825
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
42
Quarters > 1 > quarter
2025-07-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
26438
Quarters > 1 > income Statement > gross Profit
-26438
Quarters > 1 > income Statement > operating Expenses
8554548
Quarters > 1 > income Statement > operating Income
-8484235
Quarters > 1 > income Statement > interest Expense
36979
Quarters > 1 > income Statement > pretax Income
-8097264
Quarters > 1 > income Statement > net Income
-8025122
Quarters > 1 > income Statement > eps
-4.259831435326391
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
1883906
Quarters > 1 > income Statement > income Tax Expense
171855
Quarters > 1 > income Statement > EBITDA
18536388
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
386971
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
10493808
Quarters > 1 > balance Sheet > short Term Investments
7372473
Quarters > 1 > balance Sheet > receivables
563598
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
19926576
Quarters > 1 > balance Sheet > property Plant Equipment
296819
Quarters > 1 > balance Sheet > total Assets
21649706
Quarters > 1 > balance Sheet > payables
3276751
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
4315660
Quarters > 1 > balance Sheet > equity
17842989
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-8164107
Quarters > 1 > cash Flow > depreciation
26657
Quarters > 1 > cash Flow > change In Working Capital
415514
Quarters > 1 > cash Flow > cash From Operations
-8132445
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-7391000
Quarters > 1 > cash Flow > cash From Financing
13557000
Quarters > 1 > cash Flow > net Change In Cash
-1966445
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-4.259831435326391
Quarters > 1 > ratios > PB
0.0022172308686621957
Quarters > 1 > ratios > ROE
-44.97633216049172
Quarters > 1 > ratios > ROA
-37.0680414782538
Quarters > 1 > ratios > FCF
-8132445
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
41
Quarters > 2 > quarter
2025-04-30
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
27448
Quarters > 2 > income Statement > gross Profit
-27448
Quarters > 2 > income Statement > operating Expenses
6328255
Quarters > 2 > income Statement > operating Income
-6328255
Quarters > 2 > income Statement > interest Expense
36979
Quarters > 2 > income Statement > pretax Income
-6224929
Quarters > 2 > income Statement > net Income
-6126902
Quarters > 2 > income Statement > eps
-1640.402141900937
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
3735
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-6161294
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
103326
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
12460253
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
2324945
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
14785198
Quarters > 2 > balance Sheet > property Plant Equipment
319658
Quarters > 2 > balance Sheet > total Assets
17001798
Quarters > 2 > balance Sheet > payables
3279204
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
5060645
Quarters > 2 > balance Sheet > equity
12415211
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-6224929
Quarters > 2 > cash Flow > depreciation
26656
Quarters > 2 > cash Flow > change In Working Capital
-1076231
Quarters > 2 > cash Flow > cash From Operations
-7162777
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-105000
Quarters > 2 > cash Flow > cash From Financing
14714376
Quarters > 2 > cash Flow > net Change In Cash
7446599
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-1640.402141900937
Quarters > 2 > ratios > PB
0.00000631765340113833
Quarters > 2 > ratios > ROE
-49.34996271911931
Quarters > 2 > ratios > ROA
-36.036788579654925
Quarters > 2 > ratios > FCF
-7162777
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
41
Quarters > 3 > quarter
2025-01-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
7169000
Quarters > 3 > income Statement > operating Income
-7169000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-6337828
Quarters > 3 > income Statement > net Income
-6291000
Quarters > 3 > income Statement > eps
-0.3489571777235412
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
18028000
Quarters > 3 > income Statement > income Tax Expense
-6291420
Quarters > 3 > income Statement > EBITDA
-7143000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
831615
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
5013654
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
2148919
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
7162573
Quarters > 3 > balance Sheet > property Plant Equipment
342497
Quarters > 3 > balance Sheet > total Assets
9363567
Quarters > 3 > balance Sheet > payables
5003239
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
6136676
Quarters > 3 > balance Sheet > equity
3602922
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-6337828
Quarters > 3 > cash Flow > depreciation
26657
Quarters > 3 > cash Flow > change In Working Capital
870113
Quarters > 3 > cash Flow > cash From Operations
-5920222
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-75000
Quarters > 3 > cash Flow > cash From Financing
5216611
Quarters > 3 > cash Flow > net Change In Cash
-778611
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.3489571777235412
Quarters > 3 > ratios > PB
0.10507804498681904
Quarters > 3 > ratios > ROE
-174.60827628241745
Quarters > 3 > ratios > ROA
-67.18593459095236
Quarters > 3 > ratios > FCF
-5920222
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
32
Annuals > 0 > quarter
2025-07-31
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
107338
Annuals > 0 > income Statement > gross Profit
-107338
Annuals > 0 > income Statement > operating Expenses
27204803
Annuals > 0 > income Statement > operating Income
-27386315
Annuals > 0 > income Statement > interest Expense
37225
Annuals > 0 > income Statement > pretax Income
-26733324
Annuals > 0 > income Statement > net Income
-26487421
Annuals > 0 > income Statement > eps
-62.60114531781033
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
423114
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-26588760
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
652990
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
10493808
Annuals > 0 > balance Sheet > short Term Investments
7372473
Annuals > 0 > balance Sheet > receivables
563598
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
19926576
Annuals > 0 > balance Sheet > property Plant Equipment
296819
Annuals > 0 > balance Sheet > total Assets
21649706
Annuals > 0 > balance Sheet > payables
3276751
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
4315660
Annuals > 0 > balance Sheet > equity
17842989
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-26556140
Annuals > 0 > cash Flow > depreciation
106627
Annuals > 0 > cash Flow > change In Working Capital
-1919986
Annuals > 0 > cash Flow > cash From Operations
-28170520
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-7646000
Annuals > 0 > cash Flow > cash From Financing
45448239
Annuals > 0 > cash Flow > net Change In Cash
9631719
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-62.60114531781033
Annuals > 0 > ratios > PB
0.0004979767683542259
Annuals > 0 > ratios > ROE
-148.44721924112602
Annuals > 0 > ratios > ROA
-122.34540736950423
Annuals > 0 > ratios > FCF
-28170520
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
42
Annuals > 1 > quarter
2024-07-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
82583
Annuals > 1 > income Statement > gross Profit
-82583
Annuals > 1 > income Statement > operating Expenses
32725534
Annuals > 1 > income Statement > operating Income
-32808117
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-4854318
Annuals > 1 > income Statement > net Income
-4716430
Annuals > 1 > income Statement > eps
-42.994284359930354
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
109699
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-4771736
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
27953798
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
862089
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
1369016
Annuals > 1 > balance Sheet > inventories
-1369016
Annuals > 1 > balance Sheet > total Current Assets
3653854
Annuals > 1 > balance Sheet > property Plant Equipment
388175
Annuals > 1 > balance Sheet > total Assets
5872261
Annuals > 1 > balance Sheet > payables
7170781
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
8557193
Annuals > 1 > balance Sheet > equity
-2382410
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-4931548
Annuals > 1 > cash Flow > depreciation
83897
Annuals > 1 > cash Flow > change In Working Capital
7053407
Annuals > 1 > cash Flow > cash From Operations
-24126128
Annuals > 1 > cash Flow > capital Expenditures
456801
Annuals > 1 > cash Flow > cash From Investing
-681801
Annuals > 1 > cash Flow > cash From Financing
4418926
Annuals > 1 > cash Flow > net Change In Cash
-20389003
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-42.994284359930354
Annuals > 1 > ratios > PB
-0.0009669532112440764
Annuals > 1 > ratios > ROE
197.96886346178871
Annuals > 1 > ratios > ROA
-80.31710443387989
Annuals > 1 > ratios > FCF
-24582929
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2023-07-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
20490
Annuals > 2 > income Statement > gross Profit
-20490
Annuals > 2 > income Statement > operating Expenses
23272000
Annuals > 2 > income Statement > operating Income
-23272000
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-26770000
Annuals > 2 > income Statement > net Income
-20302000
Annuals > 2 > income Statement > eps
-1.2997439180537773
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
15620000
Annuals > 2 > income Statement > income Tax Expense
-153000
Annuals > 2 > income Statement > EBITDA
-27221000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
2970000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
21251092
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
717742
Annuals > 2 > balance Sheet > inventories
5671029
Annuals > 2 > balance Sheet > total Current Assets
26948507
Annuals > 2 > balance Sheet > property Plant Equipment
0
Annuals > 2 > balance Sheet > total Assets
27163577
Annuals > 2 > balance Sheet > payables
1123739
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
30940758
Annuals > 2 > balance Sheet > equity
-3777181
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-20302394
Annuals > 2 > cash Flow > depreciation
15271
Annuals > 2 > cash Flow > change In Working Capital
-3531997
Annuals > 2 > cash Flow > cash From Operations
-23744860
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
3954300
Annuals > 2 > cash Flow > net Change In Cash
-19790560
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-1.2997439180537773
Annuals > 2 > ratios > PB
-0.08684254209687066
Annuals > 2 > ratios > ROE
537.4907900892226
Annuals > 2 > ratios > ROA
-74.73978850429013
Annuals > 2 > ratios > FCF
-23744860
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
31
Annuals > 3 > quarter
2022-07-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
19385
Annuals > 3 > income Statement > gross Profit
-19385
Annuals > 3 > income Statement > operating Expenses
-3388
Annuals > 3 > income Statement > operating Income
-15289000
Annuals > 3 > income Statement > interest Expense
979
Annuals > 3 > income Statement > pretax Income
-34368000
Annuals > 3 > income Statement > net Income
-11581000
Annuals > 3 > income Statement > eps
-0.746294625596082
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
15518000
Annuals > 3 > income Statement > income Tax Expense
30730
Annuals > 3 > income Statement > EBITDA
-34047000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-11689000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
41041652
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
24103
Annuals > 3 > balance Sheet > inventories
-24103
Annuals > 3 > balance Sheet > total Current Assets
42346700
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
42577041
Annuals > 3 > balance Sheet > payables
463280
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
32248109
Annuals > 3 > balance Sheet > equity
10328932
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-26838903
Annuals > 3 > cash Flow > depreciation
15272
Annuals > 3 > cash Flow > change In Working Capital
-391292
Annuals > 3 > cash Flow > cash From Operations
-12484376
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
-3742657
Annuals > 3 > cash Flow > net Change In Cash
-16227033
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.746294625596082
Annuals > 3 > ratios > PB
0.03155001891773516
Annuals > 3 > ratios > ROE
-112.12195026552601
Annuals > 3 > ratios > ROA
-27.20010533376427
Annuals > 3 > ratios > FCF
-12484376
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
16
Valuation > metrics > PE
-4.3078959353598325
Valuation > metrics > PB
0.004231049909715131
Valuation > final Score
70
Valuation > verdict
99.6% Undervalued
Profitability > metrics > ROE
-86.79487003983999
Profitability > metrics > ROA
-71.51374637867676
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.3983406492382575
Risk > metrics > Interest Coverage
-290.88138525082076
Risk > final Score
-1104
Risk > verdict
High
Liquidity > metrics > Current Ratio
5.3306059659497915
Liquidity > metrics > Quick Ratio
5.3306059659497915
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-858
Prev Risks > 1
-625
Prev Risks > 2
-6
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
86
Updated At
2026-01-20T21:28:08.024Z
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AProfit Review: Is Gen Digital Inc. in a long term uptrend - Entry Point & Technical Pattern Based Signals baoquankhu1.vn
Read more →Will BCTXW stock outperform international peers - Quarterly Market Summary & Fast Gaining Stock Reports bollywoodhelpline.com
Read more →Showing 2 of 10
(Last Updated 2025-10-31)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of BriaCell Therapeutics Corp
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-10-31)
(Last Updated 2025-10-31)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-10-31)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-10-31)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.